The Analyst Verdict: Amgen In The Eyes Of 18 Experts
Eighteen analysts have provided ratings for Amgen (NASDAQ: AMGN) over the past three months, with current sentiments indicating 3 bullish, 4 somewhat bullish, and 11 indifferent perspectives. The average 12-month price target for Amgen is $350.61, representing a 6.93% increase from the previous average. The article also provides detailed financial insights into Amgen's market capitalization, revenue growth, net margin, ROE, ROA, and debt management.
New Amgen data highlights promise in gastric cancer
Amgen's Phase III FORTITUDE-101 clinical trial has shown positive top-line results for its FGFR2b-targeted monoclonal antibody, bemarituzumab, combined with chemotherapy, as a first-line treatment for gastric cancer. The study demonstrated statistically significant and clinically meaningful improvement in overall survival for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer. This marks a meaningful advance in developing an effective targeted therapy for a disease with high mortality and limited treatment options, with detailed results to be presented at a future medical meeting.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen Inc. (AMGN) has seen an 8.2% return over the past month, outperforming the S&P 500. Zacks analysis suggests reviewing factors like earnings estimate revisions, revenue growth forecasts, and valuation to predict its future performance. Currently, Amgen holds a Zacks Rank #3 (Hold), indicating it may perform in line with the broader market in the near term.
ICICI Prudential Asset Management Co Ltd Purchases 8,529 Shares of Amgen Inc. $AMGN
ICICI Prudential Asset Management Co Ltd increased its stake in Amgen Inc. by 35.9% in the third quarter, purchasing an additional 8,529 shares and bringing its total holdings to 32,267 shares valued at $9.11 million. Amgen recently reported strong Q3 earnings, beating analyst expectations with $5.29 EPS and $9.87 billion in revenue, also raising its quarterly dividend to $2.52 per share and providing a positive FY2026 EPS guidance. Analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $345.16.
Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More
This article compiles top Wall Street analyst upgrades, downgrades, and initiations for individual stocks on Friday, February 20, 2026. It also provides a brief overview of the market's performance, including futures, treasury bonds, oil and gas, gold, and cryptocurrency, noting that market futures are trading lower despite some positive individual company news. Key analyst calls include upgrades for ETSY and Yeti, and downgrades for Walmart and Eldorado Gold, among others, with new initiations for Amgen, GE Aerospace, and Merck.
Barclays initiates Amgen stock coverage with Equalweight rating
Barclays has initiated coverage on Amgen Inc. (NASDAQ:AMGN) with an Equalweight rating and a $350.00 price target. The firm noted that the stock is currently trading at $375.50 and is considered slightly overvalued. The rating is influenced by a negative outlook on Amgen's Phase 3 MARITIME trial, despite strong fiscal 2026 guidance and expected continued momentum for Repatha.
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More
The global stem cell and regenerative therapy market is projected to grow significantly from $16.7 billion in 2025 to $43.8 billion by 2030, driven by technological advancements and increased investments. This growth is fueled by the potential of these therapies to address various chronic health conditions such as cancer, Parkinson's, and diabetes. The market report provides a comprehensive analysis of trends, revenue forecasts, segmentation, and profiles of leading companies like Gilead Sciences, Novartis, and Bristol-Myers Squibb.
Amgen Inc. $AMGN Shares Acquired by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) during the third quarter, making it their 10th-largest holding. Amgen exceeded quarterly earnings and revenue expectations, provided strong FY2026 guidance, and recently raised its quarterly dividend. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $345.16.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Position in Amgen Inc. $AMGN
BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Amgen Inc. by 22.5% in the third quarter, holding 192,706 shares valued at over $53 million. Several other institutional investors also adjusted their positions in Amgen. The article also provides an overview of recent analyst ratings, Amgen's financial performance, and its increased quarterly dividend.
Amgen Prices $4 Billion Senior Unsecured Notes Offering
Amgen successfully raised approximately $3.96 billion through a multi-tranche senior unsecured notes offering on February 17, 2026. The notes, maturing between 2031 and 2056 with varying coupons, include investor protections such as a change-of-control provision. Amgen stock is currently rated as a Hold by analysts with a $375 price target, while TipRanks' AI Analyst, Spark, rates it as Outperform, citing strong technical strength and supportive earnings outlook despite financial risks from leverage.
Amgen raises $4bn across four tranches as Amazon lurks
Amgen successfully raised $4bn across four tranches in a recent bond offering. This move comes as "big tech's big splurge" begins to wane, with life science, utilities, and industrials now dominating supply. The article is exclusive to subscribers and details the financial activity in the high-grade and crossover bond markets.
Amgen (NASDAQ: AMGN) sells four new series of senior notes
Amgen Inc. has issued four new series of senior unsecured notes, raising net proceeds of approximately $3.96 billion. These notes, maturing between 2031 and 2056, will pay semi-annual interest and rank equally with other senior unsecured debt. The offering was conducted under an existing shelf registration, expanding Amgen's fixed-rate funding.
Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year
Palatin Technologies plans to advance two experimental obesity-targeting drugs, PL7737 and a long-acting peptide, into clinical trials this year for people with Prader-Willi syndrome (PWS) and hypothalamic obesity. These drugs are designed to activate the melanocortin-4 receptor (MC4R) to suppress hunger and are aimed at improving patient tolerability by reducing gastrointestinal side effects and hyperpigmentation, a known side effect of current MC4R agonists. The company expects to submit investigational new drug applications and initiate Phase 1 trials for both candidates in 2026.
Here's What the Street is Saying About Amgen Inc. (AMGN)
Amgen Inc. (AMGN) recently experienced a 'Hold' downgrade from Freedom Capital despite a strong Q4 2025 report, with a revised price target of $375 due to fair valuation and looming exclusivity losses. Concurrently, the European Commission approved UPLIZNA® for generalized myasthenia gravis, offering a new treatment option for patients. The company also reported robust financial performance for fiscal Q4 and full-year 2025, with double-digit growth in revenues and EPS.
Here's What the Street is Saying About Amgen Inc. (AMGN)
Amgen Inc. (AMGN) was recently downgraded to Hold from Buy by Freedom Capital, which adjusted its price target to $375, noting the shares are at fair value despite a strong Q4 report. Concurrently, Amgen received European Commission approval for UPLIZNA® as an add-on treatment for generalized myasthenia gravis. The company also reported strong fiscal Q4 and full-year 2025 results, with double-digit revenue and EPS growth.
Here’s What the Street is Saying About Amgen Inc. (AMGN)
Amgen Inc. (NASDAQ: AMGN) was recently downgraded to Hold from Buy by Freedom Capital, which adjusted its price target to $375, citing that the shares are at fair value despite a strong Q4 report. Concurrently, Amgen announced European Commission approval for UPLIZNA® for generalized myasthenia gravis and reported significant revenue and EPS growth for fiscal Q4 and full-year 2025. While Amgen is a biotechnology company with potential, the article suggests that certain AI stocks may offer more promising returns.
NewEdge Wealth LLC Raises Stock Holdings in Amgen Inc. $AMGN
NewEdge Wealth LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the third quarter, bringing their total holdings to 134,917 shares valued at $38.07 million. Several other institutional investors also adjusted their positions in Amgen. The company recently reported strong earnings, beating consensus estimates, and announced a dividend increase.
Axxcess Wealth Management LLC Boosts Stock Position in Amgen Inc. $AMGN
Axxcess Wealth Management LLC significantly increased its stake in Amgen Inc. by 59% in the third quarter, holding shares worth approximately $4.695 million. Amgen also reported strong Q3 earnings, surpassing analyst expectations for both EPS and revenue, and provided positive FY2026 guidance. Furthermore, the company raised its quarterly dividend, reflecting a healthy financial outlook and an attractive yield for investors.
Hodges Capital Management Inc. Sells 6,887 Shares of Amgen Inc. $AMGN
Hodges Capital Management Inc. significantly reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 58.6% in the third quarter, selling 6,887 shares and retaining 4,863 shares valued at $1.372 million. This move comes as Amgen reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and increased its quarterly dividend. The stock currently holds a "Moderate Buy" consensus rating from analysts, with several firms raising their price targets.
AMGN: Transformative oncology pipeline advances with T cell engagers, AI, and precision therapies
Amgen (AMGN) is making significant strides in its oncology research and development, focusing on transformative therapies for both solid and hematological cancers. Key advancements include T cell engagers, small molecules, and selective ADCs. The company's existing cancer treatments like IMDELLTRA, LUMAKRAS, and BLINCYTO are being expanded, while AI and biomarker strategies are integrated to drive further innovation and pipeline growth.
Piper Sandler Raises Amgen (AMGN) Price Target to $432 | AMGN St
Piper Sandler has increased its price target for Amgen (AMGN) to $432 from $381, while maintaining an "Overweight" rating. This decision follows a series of upward price target adjustments by other analyst firms, reflecting a generally positive outlook on Amgen's future prospects. Despite the increased price targets, the average analyst target implies a slight downside from the current price, and GuruFocus' estimated GF Value also suggests a downside.
Piper Sandler raises Amgen stock price target on drug pipeline
Piper Sandler has increased its price target for Amgen (NASDAQ: AMGN) shares from $381 to $432, reiterating an Overweight rating. This decision follows a fireside chat with Amgen senior management, discussing the expansion of Uplizna and the progress of AMG 104, along with positive Phase II results for daxdilimab and the Phase III program for dazodalibep. The revised target also incorporates updated modeling following Amgen's strong fourth-quarter 2025 results, which showed nearly 10% revenue growth and higher sales estimates for key drugs.
Amgen Stock Is Up 14% This Year on Dual Drug Approvals. Can the Rally Hold?
Amgen (AMGN) stock has risen 14% year-to-date, driven by recent FDA and European Commission approvals for its drug UPLIZNA. Despite strong revenue and EPS beats, the company missed significantly on free cash flow in Q4 2025. The article discusses analyst targets, market sentiment, and valuation models, suggesting potential upside if pipeline execution and margin recovery continue, with key catalysts including the Citi Oncology Leadership Summit and initiation of Maritide Phase 3 trials.
First National Bank of Omaha Purchases Shares of 40,836 Amgen Inc. $AMGN
First National Bank of Omaha acquired a new stake of 40,836 shares in Amgen Inc. during Q3, valued at approximately $11.52 million. Analysts currently rate Amgen as a "Moderate Buy" with a consensus price target of $354.04, and the company recently reported strong quarterly earnings that beat estimates while also increasing its quarterly dividend. Insiders have also been active, with one senior vice president selling shares in November.
Crestwood Advisors Group LLC Boosts Stake in Amgen Inc. $AMGN
Crestwood Advisors Group LLC increased its stake in Amgen Inc. by 26.2% in the third quarter, bringing their total holdings to 13,448 shares valued at $3.795 million. Other institutional investors also adjusted their positions, and hedge funds collectively own 76.50% of Amgen's stock. Amgen recently reported strong earnings, exceeding analyst expectations, and announced an increased quarterly dividend.
Wegovy copycat to be priced competitively with 50-60% discounts: Dr Reddy's
Indian drugmaker Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy at a price 50-60% lower than the branded product. The company aims to leverage the upcoming patent expiry for semaglutide in March and its recent approval for a generic Ozempic, targeting 12 million injectable pens in the first year. This move positions India as a key battleground for the expanding global weight-loss drug market.
Uveitis Clinical Trial Pipeline Expands as 15+ Companies Advance 15+ Targeted Ocular Inflammation Therapies Toward Market Entry, Finds DelveInsight | Santen, Clearside Biomedical, Tarsier Pharma
DelveInsight's report highlights an expanding pipeline for Uveitis treatments, with over 15 companies developing more than 15 targeted ocular inflammation therapies. Key players like Santen, Clearside Biomedical, and Tarsier Pharma are advancing drugs like XIPERE, YUTIQ, ILUVIEN, and TRS01, utilizing various mechanisms of action. The report details promising emerging drugs such as Tarsier Pharma's TRS01, a steroid-free ophthalmic solution, and Eyevensys' EYS606, a novel non-viral gene therapy, both showing significant potential in clinical trials.
Amgen Inc Files For Four-Part Senior Notes Offering Of Up To $4 Bln
Amgen Inc. has filed for a four-part senior notes offering, aiming to raise up to $4 billion. This financial move by the biopharmaceutical company suggests a strategy to secure capital, likely for operational expenses, debt refinancing, or future investments. The offering is expected to attract attention from investors interested in corporate bonds.
10 Health Care Stocks With Whale Alerts In Today's Session
This article highlights unusual options activity, known as "whale alerts," for ten health care stocks: AbbVie (ABBV), Abbott Laboratories (ABT), Amgen (AMGN), McKesson (MCK), Madrigal Pharmaceuticals (MDGL), Molina Healthcare (MOH), Merck & Co (MRK), Intellia Therapeutics (NTLA), UnitedHealth Group (UNH), and Vertex Pharmaceuticals (VRTX). It details specific call and put option trades, including strike prices, expiration dates, sentiment, and trade volumes, to help traders identify potential opportunities. The report explains key options terminology for better understanding of these alerts.
Amgen’s Uplizna now approved in EU to treat most adults with gMG
Amgen's Uplizna, an infusion therapy for generalized myasthenia gravis (gMG) patients positive for AChR or MuSK antibodies, has received approval for use in the European Union. This approval is significant as it provides a new treatment option that targets CD19-positive B cells, potentially reducing the long-term reliance on corticosteroids. Clinical trials for Uplizna demonstrated its efficacy in improving daily living activities and reducing muscle weakness in gMG patients with twice-yearly dosing.
Alpha Thalassemia Market to Reach US$ 1.9 Billion by 2031 | North
The global Alpha Thalassemia Market is projected to reach US$ 1.9 billion by 2031, growing from US$ 1.1 billion in 2022 at a CAGR of 7.4%. North America is expected to lead with a 35% market share, driven by advanced healthcare infrastructure and genetic testing. Key market drivers include the increasing prevalence of genetic blood disorders, diagnostic advancements, and growing awareness, with major companies like Agios Pharmaceuticals, Actis, and Novartis Pharmaceuticals Corporation shaping the market through therapeutic innovation and expanded access.
NEOS Investment Management LLC Increases Stock Position in Amgen Inc. $AMGN
NEOS Investment Management LLC increased its holdings in Amgen Inc. by 48.4% during the third quarter, adding 74,877 shares to own a total of 229,434 shares valued at $64.75 million. Other institutional investors also adjusted their positions in Amgen, with hedge funds and institutional investors collectively owning 76.50% of the stock. Analysts have recently set new price targets for Amgen, with a consensus "Moderate Buy" rating and an average target price of $354.04.
Skandinaviska Enskilda Banken AB publ Lowers Stake in Amgen Inc. $AMGN
Skandinaviska Enskilda Banken AB publ significantly reduced its stake in Amgen Inc. by 36.7% in the third quarter, selling over 91,000 shares but still retaining holdings valued at $44.37 million. Despite this, Amgen reported strong quarterly earnings, beating expectations with higher revenue and EPS, and subsequently increased its quarterly dividend. The company maintains a "Moderate Buy" consensus rating from analysts, with various institutional investors either adding to or reducing their positions.
Zions Bancorporation National Association UT Sells 10,088 Shares of Amgen Inc. $AMGN
Zions Bancorporation National Association UT reduced its stake in Amgen Inc. by 28.6% in the third quarter, selling 10,088 shares and bringing its total holdings to 25,166 shares valued at $7,102,000. This comes amidst mixed sentiment for Amgen, with positive news including European Commission approval for Uplinza and a dividend increase to $2.52 per share, countered by neutral analyst ratings and sector-level concerns. Hedge funds and other institutional investors collectively own 76.50% of the company's stock, and Amgen recently reported strong Q4 earnings, surpassing analyst estimates with $5.29 EPS and $9.87 billion in revenue.
M&G PLC Grows Position in Amgen Inc. $AMGN
M&G PLC increased its stake in Amgen Inc. by 3.8% in Q3, now owning 454,584 shares valued at approximately $128.2 million. Other institutional investors like Laurel Wealth Advisors LLC and Norges Bank also significantly adjusted their positions, with institutional ownership totaling 76.50%. Amgen reported strong Q3 earnings, beating analyst estimates, and increased its quarterly dividend to $2.52 per share, signaling confidence in future cash flow.
Vanguard Group Inc. Purchases 165,281 Shares of Amgen Inc. $AMGN
Vanguard Group Inc. increased its stake in Amgen Inc. by 0.3% in the third quarter, acquiring an additional 165,281 shares and now owning approximately 10.01% of the company, valued at over $15.2 billion. Amgen also reported strong financial results with EPS of $5.29, beating estimates, and raised its quarterly dividend to $2.52 per share, indicating management confidence in cash flow. The stock currently has a "Moderate Buy" rating from analysts with an average target price of $354.04.
Amgen Inc. $AMGN Holdings Lowered by Fifth Third Bancorp
Fifth Third Bancorp recently reduced its stake in Amgen Inc. by 1.0% in the third quarter of 2025, selling 2,975 shares and now owning 298,358 shares valued at $84.2 million. Despite this, Amgen reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, and increased its quarterly dividend to $2.52 per share. Institutional investors collectively own approximately 76.5% of Amgen's stock, while corporate insiders hold 0.69%.
Early Diagnosis Kit for Alzheimer's Disease Market Outlook
Coherent Market Insights has published a new report detailing the "Early Diagnosis Kit for Alzheimer's Disease Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report extensively covers market competition, geographic distribution, growth potential, success factors, risk assessment, and financial analysis. It also identifies major market players such as Eli Lilly, Biogen, Roche, and Abbott Laboratories, and segments the market by diagnostic methods.
Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune T Cell Pact
Vertex Pharmaceuticals has entered into an agreement with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases, marking a strategic expansion beyond its core cystic fibrosis and gene therapy pipeline. This deal gives Vertex exclusive rights to develop and commercialize the preclinical therapy, leveraging its strong financial position and R&D capabilities. While this diversification offers significant growth potential, it also introduces risks related to high R&D costs and competition in an established autoimmune market.
Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune T Cell Pact
Vertex Pharmaceuticals has partnered with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases, marking a strategic expansion beyond its core cystic fibrosis and gene therapy pipeline. This move allows Vertex to leverage its strong cash flow and scientific expertise in a new therapeutic area, despite potential R&D challenges and established competition. The company's financial performance includes US$12.0 billion revenue and US$3.95 billion net income in 2025.
Invesco 2028 Bond ETF Emerges as a Steady Anchor Amid Market Turndown
The Invesco BulletShares 2028 Corporate Bond ETF (NYSE: BSCJ) has garnered renewed investor interest as US Treasuries dipped to new annual lows and equity markets experienced heightened volatility. The ETF's focus on high-grade corporate debt offers a steady anchor with notable resilience, evidenced by stable spreads and gains in the Bloomberg Credit Index. Key factors influencing its near-term path include upcoming Federal Reserve meetings, monthly rebalancing, credit spread volatility, and inflation readings.
Shell Asset Management Co. Has $2.82 Million Stake in Amgen Inc. $AMGN
Shell Asset Management Co. reduced its stake in Amgen Inc. by 37.8% in Q3, selling 6,084 shares and ending the period with 9,992 shares valued at approximately $2.82 million. This comes as Amgen exceeded quarterly earnings and revenue estimates, reporting EPS of $5.29 against an expected $4.76 and revenue of $9.87 billion versus $9.46 billion, and raised its quarterly dividend to $2.52 per share, signaling confidence in its financial health. The company also received EC approval for Uplinza in Europe and will present at Citi's 2026 Virtual Oncology Leadership Summit, while analysts have mixed ratings with a consensus "Moderate Buy" and an average target price of $354.04.
Amgen Inc. $AMGN Shares Purchased by State of New Jersey Common Pension Fund D
The State of New Jersey Common Pension Fund D increased its stake in Amgen Inc. by 4.4% in the third quarter, now holding 188,365 shares valued at approximately $53.16 million. Amgen also reported strong fourth-quarter earnings, beating analyst expectations with $5.29 EPS and $9.87 billion in revenue, and has raised its quarterly dividend to $2.52 per share, yielding 2.7%. The company receives a "Moderate Buy" rating from analysts, with 76.5% of its stock owned by institutional investors.
A Look At Amgen (AMGN) Valuation After Strong Q4 Results And New UPLIZNA Approval
Amgen (AMGN) has seen its stock rise significantly after strong Q4 2025 results, fresh 2026 guidance, and new European approval for its drug UPLIZNA. While one valuation narrative suggests the stock is 12.6% overvalued at $327.74 compared to its current price of $369.19, a Discounted Cash Flow (DCF) model indicates it is materially undervalued at $653.95. Investors are left to weigh these differing valuations against the company's recent momentum and pipeline potential.
PNC Financial Services Group Inc. Increases Stock Holdings in Amgen Inc. $AMGN
PNC Financial Services Group Inc. increased its stake in Amgen Inc. by 10.4% in the third quarter, acquiring 105,183 additional shares to hold over 1.1 million shares valued at approximately $314.7 million. Amgen also reported strong quarterly earnings, beating analyst expectations, and raised its quarterly dividend to $2.52 per share. Analyst ratings for Amgen are mixed but average out to a "Moderate Buy" with a consensus target price of $354.04.
HighTower Advisors LLC Grows Position in Amgen Inc. $AMGN
HighTower Advisors LLC increased its stake in Amgen Inc. by 4.9% in the third quarter, bringing its total holdings to 789,377 shares valued at $222.8 million. Amgen also recently raised its quarterly dividend to $2.52 per share and reported strong financial results, surpassing revenue and EPS expectations. Several analysts have updated their ratings and price targets for Amgen, with a consensus of "Moderate Buy."
Invesco 2028 Bond ETF Emerges as a Steady Anchor Amid Market Turndown
The Invesco BulletShares 2028 Corporate Bond ETF has shown remarkable stability amidst recent equity market volatility, attracting renewed investor interest. With a low effective duration and a portfolio of high-grade corporate debt, the ETF demonstrates resilience. Investors are closely watching upcoming Federal Reserve meetings, inflation readings, and market dynamics to gauge its future performance.
ABN Amro Investment Solutions Sells 8,219 Shares of Amgen Inc. $AMGN
ABN Amro Investment Solutions has reduced its stake in Amgen Inc. by 12.5%, selling 8,219 shares and now owning 57,571 shares valued at approximately $16.25 million. This comes as Amgen reported strong Q3 results, beating analyst expectations for EPS and revenue, and raising its quarterly dividend. Insider activity also shows SVP Nancy A. Grygiel selling 3,139 shares, decreasing her position by 30.29%.
Aberdeen Group plc Sells 76,076 Shares of Amgen Inc. $AMGN
Aberdeen Group plc reduced its stake in Amgen Inc. by 11.2% in the third quarter, selling 76,076 shares and leaving them with 602,539 shares valued at $166.8 million. Other institutional investors like Cidel Asset Management Inc. and Vista Capital Partners Inc. increased their positions in Amgen during the same period. Amgen also saw an insider sale by SVP Nancy A. Grygiel and recently increased its quarterly dividend to $2.52 per share, while analysts have issued mixed ratings and price targets.
Amgen (NASDAQ:AMGN) Downgraded to "Hold" Rating by Freedom Capital
Freedom Capital downgraded Amgen (NASDAQ:AMGN) from a "strong-buy" to a "hold" rating. This comes despite several other analysts recently issuing "outperform" or "buy" ratings with increased price targets for the biotechnology company. Amgen's stock opened at $369.19, has a market cap of $198.80 billion, and recently reported strong quarterly earnings, exceeding analyst expectations, with its FY 2026 guidance forecasting 21.600-23.000 EPS.
